HIV Vaccine Trials Network

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, February 22, 2024
Biotechnology, Pharmaceutical, AIDS, Health, COVID-19, Infectious Diseases, Health Technology, Clinical Trials, Infection, Bangladesh Technical Education Board, RSV, CHB, Influenza, Peginterferon-alfa, HIV Vaccine Trials Network, GSK, Research, Investment, AASLD, HDV, MBA, Cirrhosis, HHS, Administration, Conditional sentence, Hepatology, RNA, Respiratory syncytial virus, ASPR, COVID, Patient, Family, HCMV, Bill, Development, HIV, Pharmaceutical industry

Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
  • Complete 24-week treatment data for 30 participants per regimen is expected in the fourth quarter of 2024.
  • The MARCH Part B trial is ongoing with 48-week end of treatment data expected in the fourth quarter of 2024.
  • Revenues: Total revenues for the quarter ended December 31, 2023 were $16.8 million compared to $49.4 million for the same period in 2022.

Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV

Retrieved on: 
Wednesday, September 20, 2023
Vaccine, HIV/AIDS, Conditional sentence, Joint United Nations Programme on HIV/AIDS, HIV, Public, National Institute of Allergy and Infectious Diseases, Clinical trial, Research, Antibody, Bill & Melinda Gates Foundation, Person, Bangladesh Technical Education Board, Tuberculosis, Clinical research, Immune system, Bill, HVTN, HIV Vaccine Trials Network, NIAID, Health, HCMV, UNAIDS, Infection, Safety, Disease, Malaria, Pharmaceutical industry

SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first participant has been dosed in a Phase 1 trial evaluating the safety, reactogenicity and immunogenicity of VIR-1388, an investigational novel T cell vaccine for the prevention of human immunodeficiency virus (HIV). The Company expects initial data from the Phase 1 trial in the second half of 2024.

Key Points: 
  • The Company expects initial data from the Phase 1 trial in the second half of 2024.
  • VIR-1388 was developed using applied learnings from VIR-1111, the Company’s initial investigational proof-of-concept HIV T cell vaccine based on HCMV.
  • The Phase 1 trial of VIR-1388 will take place in both domestic and international sites within the federally funded HIV Vaccine Trials Network (HVTN) as study HVTN 142.
  • The randomized, double-blind, placebo-controlled Phase 1 trial (NCT05854381) is evaluating the safety, reactogenicity and immunogenicity of three different doses of VIR-1388 compared with placebo.

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 3, 2023
HIV Vaccine Trials Network, GSK, Corporate Affairs, EASL, Sotrovimab, HIV, Investment, Influenza, Marketing, Conference call, Head, Hook effect, National Institute of Allergy and Infectious Diseases, COVID-19, Hepatitis, PEG, CHB, MBA, Infection, Bill & Melinda Gates Foundation, Bangladesh Technical Education Board, JJI, Congress, Conditional sentence, Patient, Vir, SAN, HPV, Bill, European Association of Urology, AI, NIAID, Johnson & Johnson, Viral hepatitis, Vaccine, CHD, HCMV, Conference, Pharmaceutical industry, Cryptocurrency, Dietary supplement, Management

ET, Aug. 3, 2023 –

Key Points: 
  • ET, Aug. 3, 2023 –
    SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2023.
  • Vir expects the Phase 1 trial for VIR-1388, a novel T cell vaccine for the prevention of HIV, to begin dosing in Q3 2023.
  • In June, Sasha Damouni Ellis joined Vir as Executive Vice President and Chief Corporate Affairs Officer.
  • Revenues: Total revenues for the quarter ended June 30, 2023, were $3.8 million compared to $(40.6) million for the same period in 2022.

Dallas Southern Pride Announces the 2023 Juneteenth Unity Weekend Celebration, June 16-18

Retrieved on: 
Tuesday, June 13, 2023
Yale School of Nursing, Fort Worth, Texas, HIV Vaccine Trials Network, Black and Brown!, Life, Celebration, ViiV Healthcare, Emancipation Proclamation, Social justice, Kirk, Coca-Cola, Festival, Juneteenth, Samuell, University, FHI, Freedom, Pool Party, Community Group, Culture, Georgia Southern University Southern Pride Marching Band, Black pride, Organization, Name, WarioWare, Inc.: Mega Party Games!, Gilead Sciences, LGBTQ, Crowne Plaza Hotel Billings, Burrell Communications Group, Multimedia, Houston, Beauty, Crowne Plaza, Love, Food, HIV, The Climax, Pride Month, Clothing, Yale school, Dallas Police Department, Health, Nightclub, Fireworks, Metroplex, DALLAS, KenTheMan, DFW, Black

DALLAS, June 13, 2023 /PRNewswire/ -- Dallas Southern Pride will host its highly anticipated annual Juneteenth Unity Weekend Celebration, June 16-18, 2023. This year's celebration will include a myriad of events, including the return of the sold-out Festival and Pool Party, Welcome Reception, health and wellness screenings, wellness summits, and networking mixers. The three-day weekend of festivities will commence with the Dallas Southern Pride Welcome Reception hosted by Presenting Sponsor Gilead Sciences on Friday, June 16 from 7 p.m. to 10 p.m. and Houston & New Orleans Invades Dallas party from 11 p.m. to 2 a.m. at Thrive Night Club, 1015 Elm St., Dallas, Texas, 75202. Some of the biggest names in hip-hop and entertainment, including Supahbadd and KenTheMan, are confirmed to perform at the Juneteenth Unity Festival and Pool Party on Saturday, June 17 from 5 p.m. to 10 p.m. at Samuell-Grand Aquatic Center, 3201 Samuell Blvd., Dallas, Texas. We are also highlighting several LGBTQ and local artists. The weekend will conclude with the Kirk Myers-Hill Signature Brunch from 12p.m. to 4 p.m. at the Crowne Plaza Hotel, 1015 Elm St., Dallas, Texas 75202 and "The Climax" party from 9 p.m. to 1 a.m. at Thrive Night Club.

Key Points: 
  • DALLAS, June 13, 2023 /PRNewswire/ -- Dallas Southern Pride will host its highly anticipated annual Juneteenth Unity Weekend Celebration, June 16-18, 2023.
  • "Juneteenth is an opportunity to showcase unity and display the belief that we are all stronger together," said Ahmad Goree, Dallas Southern Pride's new leader.
  • A staple in the city of Dallas during Pride Month since 2008, the 2023 Juneteenth Unity Weekend Celebration also establishes the Celebration becoming the new official Black Pride Weekend.
  • The 2022 Juneteenth Unity Weekend Celebration brought thousands of visitors to the Metroplex and sold-out all its host hotels.

Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention

Retrieved on: 
Tuesday, May 2, 2023
HIV Vaccine Trials Network, Partnership, Biotechnology, Cytomegalovirus, HIV, Public, National Institute of Allergy and Infectious Diseases, Global health, Infection, Bangladesh Technical Education Board, Investment, Tuberculosis, SAN, HIV/AIDS, Epitope, Bill, HVTN, NIAID, Bill & Melinda Gates Foundation, HCMV, Malaria, Vaccine, Pharmaceutical industry

SAN FRANCISCO, May 02, 2023 (GLOBE NEWSWIRE) --  Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it received a new $10 million grant from the Bill & Melinda Gates Foundation to support Vir’s novel T cell vaccine development program. The new grant will support the Phase 1 clinical development of VIR-1388, an investigational novel T cell vaccine for the prevention of human immunodeficiency virus (HIV). VIR-1388 is based on the human cytomegalovirus (HCMV) vector platform. Using applied learnings from VIR-1111, Vir’s initial investigational proof-of-concept HIV T cell vaccine, VIR-1388 is designed to elicit T cells that recognize different HIV epitopes with the goal of creating a safe and effective HIV vaccine. Through close scientific partnership with the National Institute of Allergy and Infectious Diseases (NIAID) and the HIV Vaccine Trials Network (HVTN), the Phase 1 trial of VIR-1388 (HVTN 142) is expected to begin in the second half of 2023. The trial will also be funded in part by NIAID, part of the National Institutes of Health, through grant funding to HVTN. NIAID has provided funding throughout the product development lifecycle of VIR-1388.

Key Points: 
  • The new grant will support the Phase 1 clinical development of VIR-1388, an investigational novel T cell vaccine for the prevention of human immunodeficiency virus (HIV).
  • Using applied learnings from VIR-1111, Vir’s initial investigational proof-of-concept HIV T cell vaccine, VIR-1388 is designed to elicit T cells that recognize different HIV epitopes with the goal of creating a safe and effective HIV vaccine.
  • “This new grant underscores the importance of our goal of developing innovative solutions for the prevention and treatment of global infectious diseases, including HIV.
  • HIV continues to be a major global public health challenge with no cure for the approximately 38 million people living with HIV infection.

LinKinVax Introduces its Scientific Advisory Board with the Appointment of Three Leading Experts in Immunology and Epidemiology

Retrieved on: 
Wednesday, April 26, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Biometrics, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, Vaccine, Immunization, Male, Hepatitis, International, Female, University, Journal of the International AIDS Society, HIV, Infection, COVID-19, DC, ANRS, Coronavirus Scientific Advisory Board, Woman, H. Lee Moffitt Cancer Center & Research Institute, Lausanne University Hospital, Doctor of Philosophy, Doherty Institute, CHUV, VRI, HIV Vaccine Trials Network, Cervical cancer, Patient, Helmholtz Centre for Infection Research, HIV/AIDS, HPV, Entrepreneurship, HVTN, Research institute, Immunology, Australian Academy of Health and Medical Sciences, Epidemiology, Laboratory, FRACP, Medicine, Cancer, Immunity

LinKinVax, a clinical-stage biotechnology company, announces the creation of its Scientific Advisory Board with the appointment of three experts in immunology and epidemiology.

Key Points: 
  • LinKinVax, a clinical-stage biotechnology company, announces the creation of its Scientific Advisory Board with the appointment of three experts in immunology and epidemiology.
  • “We are delighted to welcome Prof. Anna Giuliano, Prof. Sharon Lewin and Prof. Giuseppe Pantaleo to our Scientific Advisory Board.
  • “We are very pleased to have convinced these leading experts to join our scientific committee.
  • Their skills and experience in immunology and epidemiology will help guide and optimise all aspects of our clinical development plans for our DC-targeting vaccine platform.

Gritstone Appoints Dr. Lawrence “Larry” Corey to its Board of Directors

Retrieved on: 
Wednesday, August 10, 2022
National Institute of Allergy and Infectious Diseases, U.S. Securities and Exchange Commission, HIV/AIDS, Association, American Association, Medical laboratory, RNA transfection, GLOBE, University of Washington Department of Global Health, Diagnosis, National Center for Advancing Translational Sciences, HIV Vaccine Trials Network, HVTN, Cancer, Leadership, Fred Hutchinson Cancer Research Center, National Institute, Infection, Board, Society, Research, NIAID, Security (finance), HSV, Vaccine, COVID-19, HSV-2, Biotechnology, Alumnus, Virology, Degenerative disease, University, Board of directors, HIV, American Association of Clinical Endocrinologists, Immune system, Pharmaceutical industry, Science, Medicine, Director, Gritstone

EMERYVILLE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the worlds most potent vaccines, today announced the appointment of Lawrence Larry Corey, M.D., to its Board of Directors.

Key Points: 
  • EMERYVILLE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the worlds most potent vaccines, today announced the appointment of Lawrence Larry Corey, M.D., to its Board of Directors.
  • Effective August 12, 2022, Dr. Corey replaces Richard Heyman, Ph.D. who stepped down as a Board Member after more than six years of service.
  • I would also like to sincerely thank Rich Heyman for his years of service on Gritstones Board of Directors, where he helped us develop and apply our novel platform technologies.
  • We are thrilled to have Larry join us to help guide continued advancement of Gritstones important clinical programs and unique scientific capabilities, said Dr. Elaine V. Jones, Chair of Gritstone bios Board of Directors.

INOVIO to Present at Jefferies 2022 Healthcare Conference

Retrieved on: 
Monday, May 23, 2022
Infection, Cancer, DNA, Wistar Institute, Bill, Coalition, Coalition for Epidemic Preparedness Innovations, National Institute, Partner, HIV Vaccine Trials Network, NASDAQ, Epidemic, Therapy, Bill & Melinda Gates Foundation, National Institutes of Health, International Vaccine Institute, Walter Reed Army Institute of Research, University of Pennsylvania, Oncology, National Cancer Institute, National Institute of Allergy and Infectious Diseases, Conference, Regeneron Pharmaceuticals, University, Thermo Fisher Scientific, National, SVP, Radiation, AstraZeneca, CEO, Vaccine, Research, Chemical substance

A webcast of the presentation will be available through the INOVIO Investor Relations Events page at https://ir.inovio.com/events-and-presentations/default.aspx .

Key Points: 
  • A webcast of the presentation will be available through the INOVIO Investor Relations Events page at https://ir.inovio.com/events-and-presentations/default.aspx .
  • The presentation time is subject to change.
  • INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases.
  • Our DNA medicines are delivered using our proprietary smart device to produce a robust and tolerable immune response against targeted pathogens and cancers.

Oracle and NIH Networks Collaborate to Help End HIV

Retrieved on: 
Thursday, May 19, 2022
Cloud, Infection, HIV Vaccine Trials Network, National Institute, Multimedia, National Institute of Allergy and Infectious Diseases, View, Vaccine, COVID-19, Trial of the century, Volunteering, NIH, Research, Industry, Partnership, Awareness, Java, Fred Hutchinson Cancer Research Center, Principal, NIAID, MySQL, Pandemic, Program, Oracle Corporation, Therapy, Oracle Cloud, HIV, NYSE, Pharmaceutical industry, Software, Oracle

AUSTIN, Texas, May 19, 2022 /PRNewswire/ -- The HIV Vaccine Trials Network, funded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the NIH, today launched a new HIV awareness campaign and the Red Ribbon Registry with the goal of helping end HIV. Built by Oracle, the unique cloud-based registry makes it easy for anyone to volunteer to be considered for an HIV clinical study – getting us one step closer to a cure. To learn more or volunteer for an HIV clinical study visit https://www.helpendhiv.org/.

Key Points: 
  • Built by Oracle, the unique cloud-based registry makes it easy for anyone to volunteer to be considered for an HIV clinical study getting us one step closer to a cure.
  • The registry expands on Oracle's work with the NIH and Fred Hutchinson Cancer Center throughout the COVID-19 pandemic.
  • For more information on how Oracle is working with the U.S. and governments around the world on COVID-19 and other public health issues, visit: https://www.oracle.com/corporate/covid-19/mission/ or learn more about how you can help end HIV at https://www.helpendhiv.org/ .
  • Oracle, Java, and MySQL are registered trademarks of Oracle Corporation.

INOVIO Announces the Appointment of Jacqueline Shea, Ph.D., as Chief Executive Officer

Retrieved on: 
Tuesday, May 10, 2022
Board, United Kingdom, HIV Vaccine Trials Network, University, TB, NASDAQ, International Vaccine Institute, Regeneron Pharmaceuticals, Sabin Vaccine Institute, Coalition for Epidemic Preparedness Innovations, Tuberculosis, Company, National Institute, Medical research, Bachelor, Wistar Institute, Patient, Cell cycle, Biology, National Cancer Institute, Thermo Fisher Scientific, Clinical trial, Cancer, University of Pennsylvania, Coalition, Walter Reed Army Institute of Research, General manager, Emergent, Partner, Trustee, DNA, Epidemic, National, National Institutes of Health, Publication, Infection, Face, Vaccine, Radiation, Disease, HPV, AstraZeneca, National Institute for Medical Research, Technology, CEO, Bill, National Institute of Allergy and Infectious Diseases, Bill & Melinda Gates Foundation, Pharmaceutical industry, Research, Aera Energy, Chemical substance

PLYMOUTH MEETING, Pa., May 10, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced the appointment of Jacqueline Shea, Ph.D., as President and Chief Executive Officer (CEO) of INOVIO, effective immediately. Dr. Shea succeeds Dr. J. Joseph Kim in these roles.  Dr. Kim has also resigned as a member of the INOVIO board of directors, and the board intends to appoint Dr. Shea as a director following INOVIO's annual meeting of the stockholders on May 16, 2022.

Key Points: 
  • Mr. Simon X. Benito, Chairman of the Board of INOVIO, said, "On behalf of the entire Board, I am pleased to announce Dr. Shea's appointment as President and CEO of INOVIO.
  • Dr. Shea brings more than 25 years of experience in the life sciences and biotech industries.
  • Prior to joining INOVIO in March 2019, Dr. Shea served as the Chief Operating Officer and later the Chief Executive Officer of Aeras, a not-for-profit organization dedicated to developing new vaccines against tuberculosis (TB).
  • Previously, she held executive roles at Emergent BioSolutions and was also the General Manager and Vice President of The Oxford-Emergent Tuberculosis Consortium.